Tulsi Upadhyay

Tulsi Upadhyay

Auto-generated profile, based on publicly available information

Tulsi Upadhyay

Department of Pathology Stanford University School of Medicine Stanford United States

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 April 2020 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
ADAnirban Das
Anirban Das
YGYogesh M. Gangarde
Yogesh M. Gangarde
VTViniti Tomar
Viniti Tomar
OSOmkar Shinde
Omkar Shinde
TUTulsi Upadhyay
Tulsi Upadhyay
ISIshu Saraogi
Ishu Saraogi

27 February 2025 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
SWSijie Wang
Sijie Wang
EWEmily C. Woods
Emily C. Woods
JJJeyun Jo
Jeyun Jo
JZJiyun Zhu
Jiyun Zhu
AHAlthea Hansel-Harris
Althea Hansel-Harris
MBMatthew Bogyo
Matthew Bogyo

30 May 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
TUTulsi Upadhyay
Tulsi Upadhyay
EWEmily C. Woods
Emily C. Woods
SAStephen Dela Ahator
Stephen Dela Ahator
KJKjersti Julin
Kjersti Julin
FFFranco F. Faucher
Franco F. Faucher
MBMatthew Bogyo
Matthew Bogyo
Staphylococcus aureus is a leading cause of bacteria-associated mortality worldwide. New tools are needed to both image and treat this pathogen. We previously identified a group of S. aureus serine hydrolases (Fphs), which regulate aspects of virulence and lipid metabolism. However, due to high structural and functional similarities, it remains challenging to distinguish the specific roles of members of this family. Here, we apply a high-throughput screening approach using a library of covalent electrophiles to identify inhibitors for FphB, FphE, and FphH. We identify selective covalent inhibitors for each target without the need for extensive medicinal chemistry optimization. Structural and biochemical analysis identify novel binding modes for several of the inhibitors. Functional studies using the inhibitors suggest that all three hydrolases likely play distinct functional roles in biofilm formation and virulence. This approach has the potential to be applied to target hydrolases in other diverse pathogens or higher eukaryotes.

13 October 2021 in ChemBioChem
Verified
Journal Article
Closed access
PDF file
UPUpasana S. Potteth
Upasana S. Potteth
TUTulsi Upadhyay
Tulsi Upadhyay
SSSnehlata Saini
Snehlata Saini
ISIshu Saraogi
Ishu Saraogi

28 May 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
MUMd Jalal Uddin
Md Jalal Uddin
GRGeorge Randall
George Randall
JZJiyun Zhu
Jiyun Zhu
TUTulsi Upadhyay
Tulsi Upadhyay
LELaura van Eijk
Laura van Eijk
CLChristian Lentz
Christian Lentz
Klebsiella pneumoniae is a normal resident of the human gastro-intestinal tract and an opportunistic, critical priority pathogen that can cause a variety of severe systemic infections. Due to emerging multi-drug resistance of this pathogen, the discovery and validation of novel targets for the development of new treatment options is an urgent priority. Here, we explored the family of serine hydrolases, a highly druggable and functionally diverse enzyme family which is uncharacterized in K. pneumoniae . Using functionalized covalent fluorophosphonate inhibitors as activity-based probes we identified 10 serine hydrolases by mass spectrometry-based activity-based protein profiling, 7 of which were previously uncharacterized. Functional validation using transposon mutants deficient in either of the putative lysophospholipase PldB, esterase YjfP and patatin-like phospholipase YchK revealed severe growth defects in human colonic organoid co-culture models and reduced virulence during Galleria mellonella infection. Mutants deficient in the PldB and YjfP, but not YchK show increased susceptibility to killing by complement and the antimicrobial peptide antibiotic polymyxin B, suggesting a role in maintaining cell envelope integrity. Biochemical characterization and structural analysis of recombinant YjfP suggest this protein is a deacetylase. This study gives important insights into the molecular mechanisms underlying virulence and cell physiology of K. pneumoniae at the host-pathogen interface and it positions PldB, YjfP and YchK as potential antimicrobial or anti-virulence target candidates, inhibition of which might synergize with existing antibiotics and human immune defenses.

8 November 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
SWSijie Wang
Sijie Wang
EWEmily C. Woods
Emily C. Woods
JJJeyun Jo
Jeyun Jo
JZJiyun Zhu
Jiyun Zhu
AHAlthea Hansel-Harris
Althea Hansel-Harris
MBMatthew Bogyo
Matthew Bogyo
Staphylococcus aureus ( S. aureus ) is an opportunistic human pathogen that causes over one million deaths around the world each year. We recently identified a family of serine hydrolases termed fluorophosphonate binding hydrolases (Fphs) that play important roles in lipid metabolism and colonization of a host. Because many of these enzymes are only expressed in Staphylococcus bacteria, they are valuable targets for diagnostics and therapeutics. Here we developed and screened highly diverse cyclic peptide libraries using mRNA display with a genetically encoded oxadiazolone (Ox) electrophile that was previously shown to potently and covalently inhibit multiple Fph enzymes. By performing multiple rounds of counter selections with WT and catalytic dead FphB, we were able to tune the selectivity of the resulting selected cyclic peptides containing the Ox residue towards the desired target. From our mRNA display hits, we developed potent and selective fluorescent probes that label the active site of FphB at single digit nanomolar concentrations in live S. aureus bacteria. Taken together, this work demonstrates the potential of using direct genetically encoded electrophiles for mRNA display of covalent binding ligands and identifies potent new probes for FphB that have the potential to be used for diagnostic and therapeutic applications.